Peptron, Inc.

KOSDAQ 087010.KQ

Peptron, Inc. Capital Expenditure for the year ending December 31, 2023: USD -1.53 M

Peptron, Inc. Capital Expenditure is USD -1.53 M for the year ending December 31, 2023, a -13.11% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Peptron, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -1.36 M, a -108.97% change year over year.
  • Peptron, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -648.48 K, a 77.72% change year over year.
  • Peptron, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -2.91 M, a 33.87% change year over year.
  • Peptron, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -4.40 M, a 51.65% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
KOSDAQ: 087010.KQ

Peptron, Inc.

CEO Mr. Ho-Il Choi
IPO Date July 22, 2015
Location South Korea
Headquarters 37-24, Yuseong-daero 1628 beon-gil
Employees 94
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Frozen Foods Personal Care Pet Food Plastics
Description

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.

StockViz Staff

February 5, 2025

Any question? Send us an email